

ASX Release

25 January 2022

SENIOR PRECLINICAL DEVELOPMENT AND TRANSLATIONAL MEDICINE EXPERT TO JOIN AROVELLA

- Dr Mini Bharathan joins Arovella to lead the preclinical activities for its newly acquired DKK1 peptide targeting technology and its CAR19-iNKT cell therapy.
- Dr Bharathan has more than 15 years' experience working in the field of immunology and has spent the last 12 years specialising in the development of cell therapies, working at Intrexon, the US Department of Health (NIH/NCI), Immatics, Celgene, Celularity and Cellectis.
- Dr Bharathan joins Arovella from Cellectis, where she was a Director of Translational Medicine and Clinical Development. Cellectis is a clinical stage cell therapy company using its pioneering gene-editing platform to develop allogeneic cell therapies.

PERTH, AUSTRALIA 25 January 2022: Arovella Therapeutics Limited (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system, is pleased to announce the appointment of Dr Mini Bharathan as its VP of Development and Translational Medicine for its iNKT cell therapy platform effective 1 February 2022. Arovella recently announced that it secured the exclusive, global licence from MD Anderson to a novel monoclonal antibody targeting a DKK1 peptide, which can be used as a chimeric antigen receptor (CAR) for cell therapy. Dr Bharathan's role will encompass leading the nonclinical studies for its DKK1 technology to advance the therapy into clinical studies.

Dr Bharathan joins Arovella from Cellectis, a biotechnology company that is using its pioneering gene-editing platform to develop allogeneic therapies, which entails collecting the starting material for the cell therapy from a healthy donor as opposed to the patient suffering from the cancer.

During her time at Cellectis, Dr Bharathan served as the Director of Translational Medicine and Clinical Development where she coordinated the development programs for key products, recommended patient stratification and biomarker strategies and oversaw the development and validation of novel clinical stage assay methodologies, patient selection markers and biomarkers for multiple global allogeneic CAR-T clinical trials. Dr Bharathan also held senior roles at Celgene, Celularity and Immatics, all focused on the development of cell therapies.

Dr Bharathan has more than 15 years' experience in the field of immunology with more than 12 years focused on the development of cell therapies. Dr Bharathan is a Doctor of Veterinary Medicine and holds a PhD in immunology from Virginia Tech where she was the recipient of the Sigma Xi Outstanding Ph.D. Research Award. Dr Bharathan has co-authored numerous research articles and patents.

Arovella's CEO and MD, Dr Michael Baker, commented: "Dr Bharathan is an exceptionally talented immunologist, with many years of experience taking cell therapies from preclinical stages and into and through clinical trials, particularly allogeneic therapies. As we look to develop our iNKT cell therapy platform to advance our two cell therapy products into clinical trials, Dr Bharathan will provide immense value and we are delighted that she has decided to join Arovella."

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



For and on behalf of the Board and for further information, please contact:

Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Ltd
Tel +61 (0) 403 468 187
mbaker@arovella.com

NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human disease. Arovella's two focus areas are oncology and conditions that impact the central nervous system. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. Arovella is also developing its DKK1-peptide targeting technology licenced from MD Anderson to be used in conjunction with its iNKT cell therapy platform. The Company is developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Arovella's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA, TGA and the Ministry of Health (Chile) and is marketed in the USA. Arovella has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.